Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated May 19, 2025, reports a transaction in the company's own shares. The filing details a share repurchase executed on May 16, 2025, acting through corporate stockbroker Citigroup Global Markets Limited. The transaction is part of an existing buyback programme established via a non-discretionary agreement on February 24, 2025.
Key Financial Metrics
- Shares Purchased (May 16, 2025): 558,662 ordinary shares.
- Price Range: Lowest price paid was 1,381.00 GBp; highest price paid was 1,403.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,391.34 GBp.
- Total Buyback Volume (Since Feb 24, 2025): 43,174,335 ordinary shares.
- Treasury Shares Held: 212,244,638 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,103,014,221 ordinary shares.
- Total Voting Rights: 4,103,014,221.
Material Changes
The filing does not report material changes to revenue, profit, cash flow, or debt levels. The primary change reported is the reduction of shares in issue and the increase in treasury shares resulting from the May 16 repurchase. The total number of voting rights remains consistent with the number of shares in issue excluding treasury shares.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or management commentary regarding operational outlook. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section in GSK's 2024 Annual Report on Form 20-F and Q1 2025 Results. No unusual items or contingencies were disclosed in this specific transaction report.
Investor Verification Checklist
- Verify the total number of shares in issue (4,103,014,221) for calculating ownership percentages under FCA Disclosure Guidance and Transparency Rules.
- Confirm the cumulative buyback volume of 43,174,335 shares since the programme's inception on February 24, 2025.
- Review the specific trade execution prices (ranging from 1,381.00p to 1,403.00p) against market data for May 16, 2025.
- Check the company's 2024 Form 20-F and Q1 2025 Results for the risk factors referenced in the cautionary statement.